Abstract: A solid oral pharmaceutical composition is disclosed, which comprises: a first active ingredient, which is pitavastatin or a pharmaceutically acceptable salt thereof; a second active ingredient, which is ezetimibe or a pharmaceutically acceptable salt thereof; and at least one excipient, including a diluent, a stabilizing agent, a disintegrant, a binding agent, a sweetener, a lubricant, a glidant, a flavor, a coloring agent or a combination thereof.

Abstract: The present invention provides materials and methods of making materials, where at least one surface of the material utilizes an emulsion to controllably release active agents, which can include hydrophilic agents, into the surrounding environment. Preferably, the materials are ‘slippery’ in that liquid droplets and other compounds, such as aqueous fluids, organic compounds and microorganisms, are able to easily slide off the surface without adhering to the surface. The active agents released by the emulsion may include antimicrobial agents, antifungal agents, antibacterial agents and other molecules that can kill or otherwise reduce the number of the pathogens. The resulting materials have improved anti-fouling behaviors compared to many other existing types of anti-fouling surfaces.

Abstract: The present disclosure relates to, inter alia, a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.

Abstract: The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same.

Abstract: A sugar-responsive gel that is highly resistant to temperature changes, and a sugar-responsive drug delivery device including such a gel. The sugar-responsive gel, which comprises a gel composition including a monomer having a hydroxyl group in addition to a phenylboronic-acid-based monomer, can exhibit suitable temperature resistance. A sugar-responsive drug delivery device including such a sugar-responsive gel is less susceptible to the effects of temperature changes, and therefore can prevent undesirable excessive delivery of a drug such as insulin.

Abstract: The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.

Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.

Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.

Abstract: [Problem] Providing a whitened capsule and a whitened film without using any white pigment such as titanium dioxide. [Solution] Provided is a film, a capsule, and a film forming composition, characterized by comprising: a film-forming polymer; and a whitening agent including either a surfactant or both a surfactant and a salt, and characterized in that the surfactant is selected from a fatty acid ester of polyhydric alcohol, a polyethylene glycol, a polypropylene glycol, a polyalkylene oxide derivative, an alkyl sulfate ester salt, and a saponin.

Abstract: An apparatus for treating dry eye, comprising composition chambers respectively containing a first composition and a second composition, wherein the first composition includes 95%-100% of aqueous substances and the second composition includes 95-100% volume of non-aqueous substances; and an air pump that is fluidically connected to the composition chambers and sequentially generates and propels the mists of the first composition and the second composition to a surface that corresponds to a cornea of an eye. The first mist, including droplets of the one or more aqueous substances forms a first film layer that corresponds to an aqueous layer of an artificial tear film, the second mist has a volume within a range of 0.1-3 microliters, and includes droplets of the one or more non-aqueous substances forms a second film layer that corresponds to a lipid layer of the artificial tear film with a thickness within a range of 10 nm-200 nm.

Abstract: A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) wherein R1 and R2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and An+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that An+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H2NR1R2+?OC?ONR1R2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

Abstract: A nanoemulsion, and a method of preparing the nanoemulsion is disclosed. The nanoemulsion includes sodium hypochlorite (NaOCl), chlorhexidine (CHX), and a self-nanoemulsifying delivery system (SNEDS) which further includes at least one oil, at least one surfactant, and at least one co-surfactant, wherein no parachloroaniline is present in the nanoemulsion after 1 hour at room temperature.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: A base film for dressing and a manufacturing method thereof, and a dressing including the base film are provided. The base film includes a first region, including a composite fiber network of a micron fiber network and a nano fiber network; and a second region, including a micron fiber network. The composite fiber network in the first region and the micron fiber network in the second region are made of polymer materials.

Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Abstract: The present invention provides a microemulsion mixture, comprising a microemulsion and an active ingredient, wherein the microemulsion comprises a water phase composite, comprising a water solution and a moisturizer; an oil phase composite; and a surfactant composite; and the active ingredient is the substrate of cytochrome P450 3A4 enzyme. The microemulsion of the present invention inhibits the expression of the cytochrome P450 3A4 enzyme so as to improve the efficacy of the active ingredient in the microemulsion mixture. The present invention further provides a method of using the microemulsion mixture, a pharmaceutical microemulsion mixture comprising the microemulsion mixture, and the method for treating psoriasis comprising administering the microemulsion mixture to a subject in need thereof.